Madrigal Pharmaceuticals Inc
Suletud
SektorTervishoid
507.99 -0.44
Ülevaade
Aktsiahinna muutus
24h
Min
506.75
Max
525.59
Sissetulek | -36M -94M |
|---|---|
Müük | -9.7M 311M |
Aktsiakasum | -1.38 |
Kasumimarginaal | -30.318 |
Töötajad | 915 |
EBITDA | -36M -86M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +26.37% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | 66M 12B |
|---|---|
Eelmine avamishind | 508.43 |
Eelmine sulgemishind | 507.99 |
Uudiste sentiment
By Acuity
50%
50%
146 / 342 Pingereas Healthcare
Madrigal Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
